India, Sept. 24 -- Anlon Healthcare has rapidly gained attention as a prominent Micro-cap pharmaceutical stock, particularly following its impressive surge in September. This newfound interest is attributed to the company's strategic growth initiatives, including significant revenue increases and recent acquisitions, which have positioned it as a key player in the market, drawing the eyes of investors and analysts alike.

The stock is currently trading close to a 52-week high of Rs 29.68. It had been trading around Rs 14-15 through much of August, while its August 6 low was Rs 13.81. This means the move from the recent August low to the September peak was about 126%, although the close-to-close gain over a standard one-month window is lo...